INVAHealthcare · BiotechnologyThe 5 Wall Street analysts covering Innoviva, Inc. hold a median 12-month price target of $35 — +64.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 19 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Innoviva, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +64.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Oppenheimer | Assumes | Outperform | $35 |
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $36 → $34 |
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 22 June 2026 | BTIG | Maintains | Buy | — |
| 22 June 2026 | BTIG | Maintains | Buy | $42 |
| 1 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 May 2026 | BTIG | Reiterates | Buy | — |
| 7 May 2026 | BTIG | Maintains | Buy | — |
| 26 Feb 2026 | BTIG | Reiterates | Buy | — |
| 17 Feb 2026 | BTIG | Initiates | Buy | — |
| 16 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Sell | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2025 | Oppenheimer | Initiates | Outperform | — |
| 14 July 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 11 July 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 1 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 July 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
INVA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Oct 2026, Innoviva, Inc. returned +23.6% against +15.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 34% of US stocks
Cheaper than 62% of US stocks
Cheaper than 49% of US stocks
Higher than 68% of US stocks
Higher than 58% of US stocks
Higher than 88% of US stocks
Higher than 93% of US stocks
Higher than 98% of US stocks
Higher than 90% of US stocks
Higher than 85% of US stocks
Higher than 92% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Innoviva, Inc. has a market value of $1.5B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $440.0M. The latest quarter grew 19.3% year on year.
Net income over the same four quarters: $357.2M, a 81.2% net margin.
Diluted earnings per share, trailing twelve months: $4.10.
Free cash flow in the twelve months to 30 June 2026: $180.1M.
Innoviva, Inc. spent $56.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 4.9×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 4.74%, paying out 0% of earnings.
Innoviva, Inc. employs 159 people — $2.8M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Innoviva, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, announced it will present data from four abstracts at IDWeek 2026, scheduled for October 21–24 in Washington, D.C.
Why it matters — The presentations provide an update on the infectious disease portfolio of Innoviva Specialty Therapeutics, an Innoviva subsidiary.
Zacks Investment Research said investors should pay close attention to Innoviva (INVA) amid recent movements in its options market. The excerpt does not describe the specific options activity.
Why it matters — INVA watchers may note the reported options-market movement, though the excerpt provides no details about its direction or significance.
Zacks Investment Research compares Innoviva and Merck as potential value stocks in the Large Cap Pharmaceuticals sector. The excerpt poses which company may be more attractive to value investors but does not state a conclusion.
Why it matters — INVA watchers may find the comparison relevant when considering Innoviva’s value-investor profile alongside Merck.
Zacks Investment Research highlighted INVA among five stocks it described as having low price-to-sales ratios and promising upside potential. The item frames attractive valuations as a way to identify potential hidden value.
Why it matters — The mention puts INVA in a group singled out for its valuation profile, which may interest investors tracking the company.
Zacks Investment Research describes its approach as emphasizing earnings estimates and estimate revisions through the Zacks Rank, while also monitoring value, growth, and momentum trends. The excerpt does not provide a specific conclusion about Innoviva stock.
Why it matters — INVA watchers should note that the item frames its discussion around several investing trends but offers no company-specific assessment in the excerpt.
The 5 Wall Street analysts covering Innoviva, Inc. have a median 12-month price target of $35, with estimates ranging from $18 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Innoviva, Inc., 4 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Innoviva, Inc. 92 out of 100 across roughly 4,600 US stocks as at 19 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Oct 2026, Innoviva, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +64.5% from the last close, and Ticker Nerd's factor model ranks Innoviva, Inc. 92 out of 100 as at 19 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Innoviva, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $46 over the next 12 months.
Innoviva, Inc. returned +23.6% over the 12 months to 20 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Innoviva Inc. is a diversified biopharmaceutical company focused on healthcare assets, royalty streams, and specialty therapeutics.
The most recent item we track (Business Wire, 19 Oct 2026): "Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026". Innoviva Specialty Therapeutics, a subsidiary of Innoviva, announced it will present data from four abstracts at IDWeek 2026, scheduled for October 21–24 in Washington, D.C.
Innoviva Inc. is a diversified biopharmaceutical company focused on healthcare assets, royalty streams, and specialty therapeutics. Its core business includes a royalty portfolio tied to respiratory medicines partnered with GSK, along with ownership and management of operating healthcare businesses. Through Innoviva Specialty Therapeutics, the company develops and commercializes treatments in critical care and infectious disease, including antimicrobial and hospital-focused therapies. Innoviva also maintains strategic investments in healthcare assets and related life sciences businesses, giving it a broader role across drug development, licensing, and asset management. Headquartered in Burlingame, California, Innoviva Inc. combines recurring royalty income with product-focused operations, positioning it as a multi-asset participant in the biopharmaceutical market.
CEO Mr. Pavel Raifeld C.F.A. · 159 employees · United States · https://www.inva.com
